Medical therapies in pituitary adenomas: Current rationale for the use and future perspectives

Thomas Cuny, Anne Barlier, Richard Feelders, Georges Weryha, Leo J. Hofland, Diego Ferone, Federico Gatto

Research output: Contribution to journalArticle


Pituitary adenomas (PA) represent in the majority of cases, benign tumors whose treatment currently associate surgery, medical therapies and radiotherapy in a multidisciplinary approach. While trans-sphenoidal surgery remains, except for prolactin-secreting adenomas, the first-line treatment of PA, it can considerably be hampered by the existence of an invasive and/or aggressive tumor for which medical therapies are often requested. In this review, we extensively discuss, both at molecular and clinical levels, the medical therapies currently used and in development in the different phenotypes of pituitary adenomas.

Original languageEnglish
Pages (from-to)43-58
Number of pages16
JournalAnnales d'Endocrinologie
Issue number1
Publication statusPublished - Feb 1 2015



  • Acromegaly
  • Cushing's disease
  • Dopamin agonist
  • Pituitary adenomas
  • Somatostatin analog

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Medicine(all)

Cite this